Here's What AstraZeneca's Recent FDA News Means for Shareholders
28/5 14:15
On April 25, AstraZeneca's (NASDAQ: AZN) biologics license application for its tremelimumab and Imfinzi drug pairing was accepted by the U.S. Food and Drug Administration (FDA) to treat patients with advanced, unresectable liver cancer....